Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration, according to a study published online Oct. 10 in JAMA Ophthalmology.
(HealthDay)—Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration (AMD), according to a study published online Oct. 10 in JAMA Ophthalmology.
Megan M. McLaughlin, from GlaxoSmithKline in King of Prussia, Pa., and colleagues conducted a 14-day, placebo-controlled, dose-rising study in 72 healthy participants (oral pazopanib tablets, 5 to 30 mg daily) and a 28-day phase 2a open-label study in 15 patients with subfoveal choroidal neovascularization secondary to AMD (15 mg daily).
The researchers found that oral pazopanib was well tolerated by all. Rescue therapy before day 29 was received by six of the 15 patients, all of whom had the CFH Y402H CC "high-risk" genotype for AMD. The other nine patients completed the study without rescue with improvements from baseline in best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness. The association between the CFH Y402H T allele ("low risk" for AMD) trended toward improvement.
"It is postulated that CFH Y402H genotype may help predict which patients respond to pazopanib," the authors write.
Several authors disclosed financial ties to GlaxoSmithKline, which manufactures pazopanib and funded the study.
Explore further: Pazopanib shows better quality-of-life in advanced kidney cancer
More information: Abstract
Full Text
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Pazopanib shows better quality-of-life in advanced kidney cancer
Aug 21, 2013
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...
Impaired autophagy associated with age-related macular degeneration
Aug 21, 2013
A new study published in the prestigious PLoS One journal changes our understanding of the pathogenesis of age-related macular degeneration (AMD). The researchers found that degenerative changes and loss of vision are ca ...
Genotyping IDs long-term risk of macular degeneration
Nov 13, 2012
(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing ...
GEN reports on ocular therapeutics targeting the retina
Sep 10, 2012
Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for si ...
Supplement aids age-related macular degeneration
Mar 26, 2013
(HealthDay)—A supplement containing a combination of lutein, zeaxanthin, and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs) significantly benefits patients with age-related macular degeneration ...
Recommended for you
Team finds potential topical treatment for macular degeneration
Oct 09, 2013
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration (AMD) in a study of mice that shows ...
Blind man sees with help from tooth-implanted lens
Oct 09, 2013
(Medical Xpress)—In 1998, Ian Tibbets lost vision in his right eye, some time after he severely injured the cornea with a piece of scrap metal. Later on he also lost vision in his left eye. Tibbets was ...
Cataract surgeries on the rise as boomers age, raising access, cost issues
Oct 09, 2013
As baby boomers enter their retirement years, health care costs for complex and debilitating conditions such as Alzheimer's disease are expected to soar. Not drawing as much attention is the likelihood of similarly rising ...
Automated assessment of multiple datasets using artificial intelligence accurately diagnoses common cause of blindness
Oct 09, 2013
Pathological myopia is a condition characterized by severe, progressive nearsightedness caused by the protrusion of pigmented tissue from the back of the eye. The disease is one of the leading causes of blindness ...
Setting blurred images in motion improves perception
Sep 27, 2013
Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual ...
Improved vision from cataract surgery appears to aid survival
Sep 26, 2013
(HealthDay)—Surgical correction of visual impairment (VI) due to cataract is associated with significantly better long-term survival in older persons after adjusting for known cataract and mortality risk ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration, according to a study published online Oct. 10 in JAMA Ophthalmology.
(HealthDay)—Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration (AMD), according to a study published online Oct. 10 in JAMA Ophthalmology.
Megan M. McLaughlin, from GlaxoSmithKline in King of Prussia, Pa., and colleagues conducted a 14-day, placebo-controlled, dose-rising study in 72 healthy participants (oral pazopanib tablets, 5 to 30 mg daily) and a 28-day phase 2a open-label study in 15 patients with subfoveal choroidal neovascularization secondary to AMD (15 mg daily).
The researchers found that oral pazopanib was well tolerated by all. Rescue therapy before day 29 was received by six of the 15 patients, all of whom had the CFH Y402H CC "high-risk" genotype for AMD. The other nine patients completed the study without rescue with improvements from baseline in best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness. The association between the CFH Y402H T allele ("low risk" for AMD) trended toward improvement.
"It is postulated that CFH Y402H genotype may help predict which patients respond to pazopanib," the authors write.
Several authors disclosed financial ties to GlaxoSmithKline, which manufactures pazopanib and funded the study.
Explore further: Pazopanib shows better quality-of-life in advanced kidney cancer
More information: Abstract
Full Text
Copyright © 2013 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Pazopanib shows better quality-of-life in advanced kidney cancer
Aug 21, 2013
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...
Impaired autophagy associated with age-related macular degeneration
Aug 21, 2013
A new study published in the prestigious PLoS One journal changes our understanding of the pathogenesis of age-related macular degeneration (AMD). The researchers found that degenerative changes and loss of vision are ca ...
Genotyping IDs long-term risk of macular degeneration
Nov 13, 2012
(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing ...
GEN reports on ocular therapeutics targeting the retina
Sep 10, 2012
Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for si ...
Supplement aids age-related macular degeneration
Mar 26, 2013
(HealthDay)—A supplement containing a combination of lutein, zeaxanthin, and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs) significantly benefits patients with age-related macular degeneration ...
Recommended for you
Team finds potential topical treatment for macular degeneration
Oct 09, 2013
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration (AMD) in a study of mice that shows ...
Blind man sees with help from tooth-implanted lens
Oct 09, 2013
(Medical Xpress)—In 1998, Ian Tibbets lost vision in his right eye, some time after he severely injured the cornea with a piece of scrap metal. Later on he also lost vision in his left eye. Tibbets was ...
Cataract surgeries on the rise as boomers age, raising access, cost issues
Oct 09, 2013
As baby boomers enter their retirement years, health care costs for complex and debilitating conditions such as Alzheimer's disease are expected to soar. Not drawing as much attention is the likelihood of similarly rising ...
Automated assessment of multiple datasets using artificial intelligence accurately diagnoses common cause of blindness
Oct 09, 2013
Pathological myopia is a condition characterized by severe, progressive nearsightedness caused by the protrusion of pigmented tissue from the back of the eye. The disease is one of the leading causes of blindness ...
Setting blurred images in motion improves perception
Sep 27, 2013
Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual ...
Improved vision from cataract surgery appears to aid survival
Sep 26, 2013
(HealthDay)—Surgical correction of visual impairment (VI) due to cataract is associated with significantly better long-term survival in older persons after adjusting for known cataract and mortality risk ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment